CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Phase 2

CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Sponsor:

BioAtla, Inc.

Code:

NCT04681131

Conditions

Non-Small-Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CAB-AXL-ADC

PD-1 inhibitor

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information